A French biotech that has earned some global attention for its early-stage work on a hepatitis C vaccine has revealed the name of its mystery buyer. Cambridge, MA-based VBI is acquiring Epixis for an undisclosed sum, touting the potential of its work using next-gen virus-like particles in its treatments. "This acquisition enables VBI to strategically build upon our pipeline of innovative vaccine delivery technologies and advance the development of an extremely promising VLP platform," said VBI President and CEO Jeff Baxter. VBI and Epixis forged a VLP research collaboration focused on cytomegalovirus last year. VBI release